The Inven2 start-up portfolio

Nordic-American Life Science Conference 2018

Ole Kristian Hjelstuen, CEO

Disclaimer

• This presentation may contain certain forward-looking statements and forecasts based on best current knowledge. No assurance can be given that expectations arising from this presentation will prove to have been correct. Inven2 disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Inven2 is the Tech Transfer Office for

• The University of Oslo

• Oslo University Hospital, including the National Cancer Hospital

• All hospitals in South Eastern Norway, serving 50% of the Norwegian population

From Science to Business in Norway

Inven2 has, alone or jointly, started companies like

Nordic Nanovector

• Pharmaceutical company

• Listed on the Norwegian Stock Exchange main list

• Haematological cancers

• Betalutin – Non-Hodgkin’s Lymphoma – Phase II

CD37: the treatment target for Betalutin®

Antibody-177Lu conjugate

Figure from www.nordicnanovector.com

Vaccibody

• Tailored vaccine therapy

• Targeting Antigen Presenting Cells

• Phase I/IIa – HPV16-vaccine to treat precancerous cervical lesions

Figure from www.vaccibody.com

Ultimovacs

• Pharmaceutical company

• Pre-IPO

• UV1 – peptide based product

• Targeting telomerase (hTert)

• Phase I/IIa Cancer Therapeutic

• Ongoing studies in Lung, Prostate and Melanoma

Epiguard

• Medtech company • Patient isolation unit – patent pending • Established 2015 • Approved device – on the market in Europe – pending FDA approval • Pre-IPO

Our start-up portfolio

Status

Inven2 has established 82 companies

–15 exits

–45 active companies

–22 companies closed

Excellence in idea selection process

Idea selection

Company establishment

Verification, Project development

New start-ups

Cancer treatment using T-cells equipped with targeting units – CARs or TCRs – that seek out and kill cancer cells independently of their location in the patient

Preclinical phase to first patient

Adoptive T-Cell Therapy of Cancer

CAR: Chimeric Antigen Receptor TCR: T-Cell Receptor

Serca Pharmaceuticals Novel therapy for ischemic reperfusion injury

• Est Nov 2018

• US patent granted

• EU & J pat pending

• Radspherin® - 224Ra-microparticles • Peritoneal carcinomatosis • GMP Production labs complete • Product ready for phase I/II

Knut Erik Hovda

OUS

Gaut Gadeholt

OUS

Dag Jacobsen

OUS

Åsmund R. Kjendseth

NMBU

Orphan Diagnostics

MeTOX – Point-of-care methanol poisoning test. Validated for use

- 1 drop of blood – read-out after 3 minutes

- Single use product

- Simple to use

- Low production costs

Project pipeline

most advanced projects

PDE2 inhibition as a new therapeutic strategy for ventricular arrhythmias

• Novel mechanism of action for prevention of arrhythmias, likely to provide higher selectivity and fewer safety issues than current options

• Proof of concept demonstrated in two separate mouse models of disease, with two different PDE inhibitors

• Securing soft funding for 2019, possible start-up mid 2019

Lethal cardiac arrhythmia with control treatment

Normal heart rhythm with PDE inhibitor

Antibiotic complement drug against multi-resistance

• ZinChel, complement to beta-lactam antibiotics

• Lead cmpd ZN148 is only drug acting on resistance mechanism metallobetalactamase NDM, VIM, IMP

• ZN148 works on «New Dehli – bacteria» - the NDM-1 superbug.

• Preclinical phase • Soft funding one more yr • Collaboration project,

several universities

Normal self Peptide (CD20p)

Patient HLA

Normal self peptide (CD20p)

Patient HLA

Immunooncology: TCR factory

Lead product: A CD20-targeted T-cell receptor (TCR) for treatment of B-cell lymphoma

Competitiveness: Identification of high-potency TCRs from donor T cells (patented method)

Donor TCR Patient TCR

Patient B cell

Donor T cell Patent application: WO 2015/071763A2

Kumari et al, PNAS 2014, Stronen et al, Science 2016

Patient T cell

70 ongoing projects

• We are looking for investors who wants to enter the company initiation phase

• Visit www.inven2.com

• contact me on o.k.hjelstuen@inven2.com

• +47 90824724

@inven2as